|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Aliskiren#Overdosage]] |
| {{Aliskiren}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Overdosage==
| |
| | |
| | |
| Limited data are available related to overdosage in humans. The most likely manifestation of overdosage would be [[hypotension]]. If symptomatic [[hypotension]] occurs, supportive treatment should be initiated.
| |
| | |
| Aliskiren is poorly dialyzed. Therefore, [[hemodialysis]] is not adequate to treat aliskiren overexposure [see Clinical Pharmacology (12.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TEKTURNA (ALISKIREN HEMIFUMARATE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=833c7a0b-5f64-4363-94d5-9a179049113a | publisher = | date = | accessdate = 25 February 2014 }}</ref> | |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Agents acting on the renin-angiotensin system}}
| |
| | |
| [[Category:Renin inhibitors]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |